157 related articles for article (PubMed ID: 25142001)
1. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).
Lee CS; Ashton-Key M; Cogliatti S; Rondeau S; Schmitz SF; Ghielmini M; Cragg MS; Johnson P
Br J Haematol; 2015 Jan; 168(1):145-8. PubMed ID: 25142001
[No Abstract] [Full Text] [Related]
2. FCGR3A polymorphism story: a new piece of the puzzle.
Cartron G
Leuk Lymphoma; 2009 Sep; 50(9):1401-2. PubMed ID: 19672769
[No Abstract] [Full Text] [Related]
3. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Weng WK; Levy R
J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
[TBL] [Abstract][Full Text] [Related]
4. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
Ghesquières H; Cartron G; Seymour JF; Delfau-Larue MH; Offner F; Soubeyran P; Perrot A; Brice P; Bouabdallah R; Sonet A; Dupuis J; Casasnovas O; Catalano JV; Delmer A; Jardin F; Verney A; Dartigues P; Salles G
Blood; 2012 Sep; 120(13):2650-7. PubMed ID: 22885164
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
7. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.
Nabhan C; Smith SM; Kahl BS
Leuk Lymphoma; 2012 May; 53(5):770-8. PubMed ID: 21958083
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.
Weng WK; Levy R
Leuk Lymphoma; 2009 May; 50(5):723-7. PubMed ID: 19452316
[TBL] [Abstract][Full Text] [Related]
9. Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
Croxtall JD
BioDrugs; 2011 Oct; 25(5):329-31. PubMed ID: 21942917
[No Abstract] [Full Text] [Related]
10. [Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy].
Koch R; Sander CA
Hautarzt; 2010 Nov; 61(11):976-9. PubMed ID: 20221574
[TBL] [Abstract][Full Text] [Related]
11. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
Roy R; Gordon LI
J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
[TBL] [Abstract][Full Text] [Related]
12. Variation in gene expression patterns in follicular lymphoma and the response to rituximab.
Bohen SP; Troyanskaya OG; Alter O; Warnke R; Botstein D; Brown PO; Levy R
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1926-30. PubMed ID: 12571354
[TBL] [Abstract][Full Text] [Related]
13. Hematology: Rituximab for follicular lymphoma: maintaining an open mind.
Cheson BD
Nat Rev Clin Oncol; 2011 May; 8(5):257-8. PubMed ID: 21403667
[No Abstract] [Full Text] [Related]
14. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.
Sarkozy C; Seymour JF; Ferme C; Caballero D; Ghesquieres H; Leppa S; Delarue R; Pedersen LM; Mounier C; Gomes Da Silva M; Chassagne-Clement C; Maerevoet M; Salles G
Blood; 2014 Apr; 123(17):2740-2. PubMed ID: 24764560
[No Abstract] [Full Text] [Related]
15. Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story? Reply to "Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone". Haematologica. 2012;97(6):937-942.
Procházka V; Gazdová J; Papajík T
Haematologica; 2012 Nov; 97(11):e45; author reply e46. PubMed ID: 23125245
[No Abstract] [Full Text] [Related]
16. Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL.
Jones B
Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 23999211
[No Abstract] [Full Text] [Related]
17. Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.
Kenkre VP; Hong F; Cerhan JR; Lewis M; Sullivan L; Williams ME; Gascoyne RD; Horning SJ; Kahl BS
Clin Cancer Res; 2016 Feb; 22(4):821-6. PubMed ID: 26510856
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment.
Cartron G; Ohresser M; Salles G; Solal-Céligny P; Colombat P; Watier H
Ann Oncol; 2008 Aug; 19(8):1485-1487. PubMed ID: 18408222
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
20. Follicular lymphoma: watch and wait is watch and worry.
Ansell SM
Lancet Oncol; 2014 Apr; 15(4):368-9. PubMed ID: 24602759
[No Abstract] [Full Text] [Related]
[Next] [New Search]
